Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability Study of BIIB122 (DNL151) in Healthy Subjects
NCT05005338Phase 1Completed
- Sponsor
- Biogen
- Start
- Jul 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BIIB122 in Parkinson's disease (PD), sponsored by Biogen. Primary endpoints: Time to Maximum Observed Concentration at 21 days, Maximum Observed Concentration at 21 days and 5 more. Started Jul 2021; status: completed.
02
Drugs
BIIB122
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05005338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005338.